Cost of Illness of Glaucoma
Tóm tắt
Cost-of-illness studies determine the total financial burden of a disease by considering direct and indirect costs, including medication, diagnostics and surgery. Studies of resource use and costs associated with primary open-angle glaucoma have used varying methodologies. Most have focused on consumption of healthcare resources at various stages of disease to anticipate costs. The direct costs associated with the disease often continue to increase as glaucoma progresses from the earliest to most advanced stages. Determinations of the costs associated with glaucoma progression and prevention should also incorporate the chance of patient non-compliance with treatment. Since glaucoma severity most often correlates with increased costs, minimizing or halting visual field loss and increasing patient treatment compliance may all contribute to a reduction in the overall economic burden of glaucoma.
Tài liệu tham khảo
The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000 Oct; 130 (4): 429–40
Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004 Apr; 15 (2): 102–6
Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998 Oct; 126 (4): 487–97
Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998 Oct; 126 (4): 498–505
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262–7
Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patients management. A review. Drugs Aging 2005; 22: 315–21
Akobundu E, Ju J, Blatt L, et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006; 24 (9): 869–90
Ellwein LB, Urato CJ. Use of eye care and associated charges among the Medicare population: 1991–1998. Arch Ophthalmol 2002; 120: 804–11
Gieser DK, Williams RT, O’Connell W. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma 2006; 15: 419–25
Iskedjian M, Walker J, Vicente C, et al. Cost of glaucoma in Canada: analyses based on visual field and physician’s assessment. J Glaucoma 2003; 12: 456–62
Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006; 124: 12–9
Lee PP, Levin LA, Walt JG, et al. Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data. Ophthalmology 2007; 114: 1241–7
Rein DB, Zhan P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006; 124: 1754–60
Vicente C, Walker J, Buys Y, et al. Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada. Curr Med Res Opin 2004; 32: 1245–51
Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004; 13: 283–90
Koleva D, Motterlini N, Schiavone M, et al. Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study. Ophthalmologica 2007; 221: 340–7
Lindblom B, Nordmann JP, Sellem E, et al. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 2006; 82: 73–83
Neymark N, Buchholz P, Honrubia F, et al. The costs of treating glaucoma with combinations of topical drugs in Spain. Eur J Ophthalmol 2008; 18: 52–9
Oostenbrink JB, Rutten-van Molken MP, Opdenoordt TS. The treatment of newly diagnosed patients with glaucoma or with ocular hypertension in the Netherlands: an observational study of costs and initial treatment success based on retrospective chart review. Doc Ophthalmol 1999; 98: 285–99
Oostenbrink JB, Rutten-van Molken MP, Sluyter-Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001; 10: 184–91
Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilization in Europe. Br J Ophthalmol 2005; 89: 1245–9
Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998; 7: 95–104
Lee PP, Kelly SP, Mills RP, et al. Glaucoma in the United States and Europe: predicting costs and surgical rates based upon stage of disease. J Glaucoma 2007; 16: 471–8
Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics 2007; 25 (4): 287–308
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701–13
Goldberg LD. Disease management programs for glaucoma: has the vision become a reality? Dis Manage Health Outcomes 2007; 15 (4): 199–205
Nordmann JP, Lafuma A, Deschaseaus C, et al. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. J Glaucoma 2005; 14: 463–9
Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology 2005; 112: 953–61
Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006; 141: S28–33
Lee PP, Walt JG, Chiang TH, et al. A gap analysis approach to assess patient persistence with glaucoma medication. Am J Ophthalmol 2007; 144: 520–4
Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140: 598–606
Tingey D, Bernard LM, Grima DT, et al. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension. Can J Ophthalmol 2005; 40 (2): 161–9
Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533–40